[go: up one dir, main page]

CY1116156T1 - Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο - Google Patents

Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο

Info

Publication number
CY1116156T1
CY1116156T1 CY20141100782T CY141100782T CY1116156T1 CY 1116156 T1 CY1116156 T1 CY 1116156T1 CY 20141100782 T CY20141100782 T CY 20141100782T CY 141100782 T CY141100782 T CY 141100782T CY 1116156 T1 CY1116156 T1 CY 1116156T1
Authority
CY
Cyprus
Prior art keywords
compounds
oxygen
products connected
pyrimidine
treatment
Prior art date
Application number
CY20141100782T
Other languages
English (en)
Inventor
Stéphanie Blanchard
Cheng Hsia Angeline Lee
Harish Kumar Mysore Nagaraj
Anders Poulsen
Eric T Sun
Yee Ling Evelyn Tan
Anthony Deodaunia William
Original Assignee
Cti Biopharma Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cti Biopharma Corp. filed Critical Cti Biopharma Corp.
Publication of CY1116156T1 publication Critical patent/CY1116156T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε ενώσεις πυριμιδίνης που είναι χρήσιμες ως αντιπολλαπλασιαστικοί παράγοντες. Πιο συγκεκριμένα, η παρούσα εφεύρεση αναφέρεται σε συνδεδεμένες με οξυγόνο και υποκατεστημένες ενώσεις πυριμιδίνης, μεθόδους για την παρασκευή τους, φαρμακευτικές συνθέσεις που περιέχουν αυτές τις ενώσεις και τις χρήσεις των ενώσεων αυτών στην αντιμετώπιση των πολλαπλασιαστικών διαταραχών. Οι ενώσεις αυτές ενδέχεται να είναι χρήσιμες ως φαρμακευτικές ουσίες για την αντιμετώπιση διαφόρων πολλαπλασιαστικών διαταραχών που περιλαμβάνουν τους όγκους και τους καρκίνους, καθώς επίσης και άλλες διαταραχές ή παθήσεις που συνδέονται με τις κινάσες.
CY20141100782T 2005-11-16 2014-09-25 Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο CY1116156T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73683805P 2005-11-16 2005-11-16
US81733906P 2006-06-30 2006-06-30
US85128306P 2006-10-13 2006-10-13
EP06813132.5A EP1951729B1 (en) 2005-11-16 2006-11-15 Oxygen linked pyrimidine derivatives

Publications (1)

Publication Number Publication Date
CY1116156T1 true CY1116156T1 (el) 2017-02-08

Family

ID=38048928

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100782T CY1116156T1 (el) 2005-11-16 2014-09-25 Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο

Country Status (20)

Country Link
US (5) US8143255B2 (el)
EP (1) EP1951729B1 (el)
JP (2) JP5380073B2 (el)
KR (5) KR101513492B1 (el)
CN (2) CN101365703B (el)
AT (1) ATE469158T1 (el)
AU (2) AU2006316071B2 (el)
BR (1) BRPI0618552B8 (el)
CA (2) CA2629443C (el)
CY (1) CY1116156T1 (el)
DE (1) DE602006014579D1 (el)
DK (2) DK1951729T3 (el)
ES (2) ES2346791T3 (el)
MY (1) MY148072A (el)
NZ (1) NZ568325A (el)
PH (1) PH12012501003B1 (el)
PL (1) PL1951729T3 (el)
PT (2) PT1951729E (el)
TW (3) TWI525096B (el)
WO (2) WO2007058627A1 (el)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06007017A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
BR122021011788B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US10517876B2 (en) * 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
AU2007274284B2 (en) * 2006-07-13 2012-04-26 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
KR20090125155A (ko) * 2007-03-01 2009-12-03 추가이 세이야쿠 가부시키가이샤 마크로 고리상 화합물
WO2008140419A2 (en) * 2007-05-15 2008-11-20 S*Bio Pte Ltd Pyridyl substituted pyrimidine derivatives
WO2008140420A2 (en) * 2007-05-15 2008-11-20 S*Bio Pte Ltd Pyrimidine derivatives
WO2009009778A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
EP2185562B1 (en) 2007-07-27 2015-12-02 Janssen Pharmaceutica, N.V. Pyrrolopyrimidines useful for the treatment of proliferative diseases
DK2283024T3 (da) * 2008-03-10 2013-08-05 Janssen Pharmaceutica Nv 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer
JP2011518836A (ja) 2008-04-24 2011-06-30 インサイト・コーポレイション 大環状化合物およびそれらのキナーゼ阻害剤としての使用
AU2009325147B2 (en) * 2008-12-11 2014-08-14 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
HRP20150413T8 (xx) * 2008-12-11 2015-08-14 Cti Biopharma Corp. 11-(2-pirolidin-1-il-etoksi)-14,19-dioksa-5,7,26-triaza-tetraciklo[19.31.1(2,6).1(8,12)]heptakoza-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaen maleatna sol
BR112012000750B1 (pt) 2009-07-15 2021-05-25 Cti Biopharma Corp. sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo
ES2632548T3 (es) * 2010-02-05 2017-09-14 Tragara Pharmaceuticals, Inc. Formas de estado sólido de los inhibidores de la quinasa macrocíclica
TW201206946A (en) * 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN102127087B (zh) * 2011-01-21 2012-07-04 江苏先声药物研究有限公司 喹唑啉衍生物
CN102757448B (zh) * 2011-04-26 2016-04-06 中南大学 大环类激酶抑制剂化合物、制备方法及其作为药物的应用
JP6082397B2 (ja) * 2011-09-30 2017-02-15 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． マクロ環状ｌｒｒｋ２キナーゼ阻害剤
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
CN102617599B (zh) * 2012-04-10 2014-04-16 江苏先声药物研究有限公司 大环类化合物及其应用
CA2904148A1 (en) * 2013-03-14 2014-10-02 Concert Pharmaceuticals, Inc. Deuterated pacritinib
WO2014180524A1 (en) * 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
MA39822A (fr) * 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) * 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
ES2921875T3 (es) 2014-08-11 2022-09-01 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
FR3025200B1 (fr) * 2014-09-02 2016-09-23 Pf Medicament Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques
FR3025199B1 (fr) * 2014-09-02 2016-09-23 Pf Medicament Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques
CA2960777A1 (en) 2014-09-17 2016-03-24 Oncodesign S.A. Macrocyclic lrrk2 kinase inhibitors
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
WO2016149031A1 (en) * 2015-03-18 2016-09-22 Newave Pharmaceutical Llc Covalent inhibitors of cdk-7
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法
CN105017282B (zh) * 2015-08-28 2017-11-07 苏州明锐医药科技有限公司 帕克替尼的制备方法
US20180318306A1 (en) * 2015-09-28 2018-11-08 Cti Biopharma Corp. Methods of treating transplant rejection
JP6888000B2 (ja) * 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト 新規な修飾された大環状化合物
WO2017165732A1 (en) 2016-03-24 2017-09-28 Tragara Pharmaceuticals, Inc. Treatment of cancer with tg02
WO2017196261A1 (en) * 2016-05-11 2017-11-16 National University Of Singapore Jak and hdac dual-inhibitor compounds
AU2018317865B2 (en) * 2017-08-18 2023-03-16 Cothera Bioscience, Inc. Polymorphic form of TG02
WO2019079357A1 (en) * 2017-10-17 2019-04-25 Silverback Therapeutics, Inc. TNIK MODULATORS, CONJUGATES AND USES THEREOF
CN108864145B (zh) * 2018-09-14 2021-03-30 兆科（广州）肿瘤药物有限公司 一种氧联嘧啶衍生物的纯化方法
US20230183204A9 (en) * 2018-11-07 2023-06-15 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
CN111269245B (zh) * 2018-12-04 2021-08-27 杭州百新生物医药科技有限公司 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
CN111989332B (zh) * 2018-12-19 2022-07-26 凯复(苏州)生物医药有限公司 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
WO2020219606A1 (en) * 2019-04-22 2020-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of erk5 inhibitors for treating gliomas in pediatric subjects
WO2020257644A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2020256739A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2021091535A1 (en) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
JP7671284B2 (ja) 2019-10-04 2025-05-01 ティーエーイー ライフ サイエンシーズ Ｆｃ変異および部位特異的コンジュゲーション特性を含む抗体組成物
CN113583020B (zh) * 2020-04-30 2022-04-22 百极弘烨（广东）医药科技有限公司 一种jak2抑制剂及应用
CN113735879B (zh) * 2020-05-27 2022-05-17 百极弘烨（广东）医药科技有限公司 一种大环jak抑制剂及其应用
WO2022056092A1 (en) * 2020-09-11 2022-03-17 Cti Biopharma Corp. Methods of treating viral infection
CN115490705B (zh) * 2021-06-18 2025-04-01 成都凡诺西生物医药科技有限公司 N-大环酰胺类化合物、其制备方法及其作为药物的应用
CN113603708B (zh) * 2021-07-27 2023-08-11 中国药科大学 一种具有大环骨架结构的cdk9抑制剂的制备及其应用
CN114409674B (zh) * 2022-01-28 2023-07-25 山东大学 一种JAK抑制剂Pacritinib的合成方法
CN117964628A (zh) * 2022-10-24 2024-05-03 科辉智药生物科技(深圳)有限公司 作为cdk9抑制剂的大环类化合物及其应用
CN117447407B (zh) * 2023-12-19 2024-06-11 潍坊医学院 一种JAK2抑制剂Pacritinib及其中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
BR9810488A (pt) 1997-06-27 2000-09-12 Ciba Sc Holding Ag Novos catalisadores.
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
JP4492348B2 (ja) * 2002-10-29 2010-06-30 萬有製薬株式会社 新規キノキサリノン誘導体
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
US7163939B2 (en) * 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US20050096324A1 (en) * 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
MXPA06007017A (es) * 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
EP1696914B1 (en) * 2003-12-18 2009-10-28 Janssen Pharmaceutica N.V. 3-cyano-quinoline derivatives with antiproliferative activity
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
US9047780B2 (en) * 2012-11-16 2015-06-02 Robert Bosch Gmbh Collision mitigation systems and methods using driver attentiveness

Also Published As

Publication number Publication date
CN101360751B (zh) 2011-09-14
EP1951729B1 (en) 2014-06-25
CN101360751A (zh) 2009-02-04
ES2506040T3 (es) 2014-10-13
TW201418263A (zh) 2014-05-16
KR20140037256A (ko) 2014-03-26
TWI407961B (zh) 2013-09-11
US20090258886A1 (en) 2009-10-15
NZ568325A (en) 2011-05-27
ES2346791T3 (es) 2010-10-20
US20120196855A1 (en) 2012-08-02
TWI506029B (zh) 2015-11-01
KR20140117679A (ko) 2014-10-07
BRPI0618552A2 (pt) 2011-09-06
KR20080090390A (ko) 2008-10-08
AU2006316072B2 (en) 2011-12-22
TWI525096B (zh) 2016-03-11
CA2629455A1 (en) 2007-05-24
KR20140037257A (ko) 2014-03-26
HK1124040A1 (en) 2009-07-03
AU2006316071A1 (en) 2007-05-24
DK1951730T3 (da) 2010-09-27
US9133214B2 (en) 2015-09-15
ATE469158T1 (de) 2010-06-15
KR101568801B1 (ko) 2015-11-12
US8153632B2 (en) 2012-04-10
PT1951730E (pt) 2010-08-27
CA2629443C (en) 2016-12-13
AU2006316072A1 (en) 2007-05-24
JP2009517344A (ja) 2009-04-30
DK1951729T3 (da) 2014-10-06
EP1951729A1 (en) 2008-08-06
JP5380073B2 (ja) 2014-01-08
AU2006316071B2 (en) 2011-02-17
JP2009515954A (ja) 2009-04-16
PH12012501003B1 (en) 2018-04-06
CN101365703A (zh) 2009-02-11
TW200738735A (en) 2007-10-16
BRPI0618552B8 (pt) 2021-05-25
CN101365703B (zh) 2013-11-06
MY148072A (en) 2013-02-28
KR101513492B1 (ko) 2015-04-20
US20120142680A1 (en) 2012-06-07
JP5225856B2 (ja) 2013-07-03
US8415338B2 (en) 2013-04-09
US20130172338A1 (en) 2013-07-04
CA2629443A1 (en) 2007-05-24
PT1951729E (pt) 2014-10-02
CA2629455C (en) 2017-01-03
KR101499594B1 (ko) 2015-03-09
US8143255B2 (en) 2012-03-27
BRPI0618552B1 (pt) 2021-04-06
DE602006014579D1 (de) 2010-07-08
PL1951729T3 (pl) 2015-02-27
TW200736262A (en) 2007-10-01
WO2007058628A1 (en) 2007-05-24
US20090075999A1 (en) 2009-03-19
KR20080086443A (ko) 2008-09-25
PH12012501003A1 (en) 2012-10-29
US9573964B2 (en) 2017-02-21
EP1951729A4 (en) 2009-09-23
WO2007058627A1 (en) 2007-05-24
HK1123282A1 (en) 2009-06-12
KR101576159B1 (ko) 2015-12-09

Similar Documents

Publication Publication Date Title
CY1116156T1 (el) Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1121848T1 (el) Διυποκατεστημενα οκταϋδροπυρρολο [3,4-c]πυρρολια ως ρυθμιστες υποδοχεα ορεξινης
CY1117319T1 (el) Τρικυκλικα παραγωγα αμινης ως αναστολεις πρωτεϊνικης τυροσινης κινασης
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
NZ752526A (en) Pyrrolobenzodiazepine conjugates
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1108186T1 (el) Παραγωγα κουιναζολινης ως αναστολεις της κινασης τυροσινης
CY1113160T1 (el) Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
CY1108408T1 (el) Παραγωγα διαζεπινοϊνδολιου ως αναστολεις κινασης
CY1116057T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
CY1116929T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
CY1113323T1 (el) Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου
CY1113665T1 (el) Θετικοι αλλοστερικοι ρυθμιστες του υποδοχεα μ1 με αρυλομεθυλο βενζοκιναζολινονη
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
CY1114952T1 (el) Ενεργοποιητες θειενο[2,3-b]πυριδινοδιονης της αμρκ και θεραπευτικες χρησεις αυτων
CY1110190T1 (el) Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38
CY1117504T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1
CY1114989T1 (el) ΠΑΡΑΓΩΓΑ ΤΗΣ ΠΥΡΙΔΟ[2,3-d]ΠΥΡΙΜΙΔΙΝΗΣ, Η ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ ΚΑΙ Η ΕΦΑΡΜΟΓΗ ΤΟΥΣ ΣΕ ΘΕΡΑΠΕΥΤΙΚΕΣ ΑΓΩΓΕΣ
CY1113146T1 (el) 11-φωσφο-στεροειδη παραγωγα ως τροποποιητες του υποδοχεα προγεστερονης
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
CY1117577T1 (el) Υποκατεστημενα φουρανοκαρβοξαμιδια και χρηση αυτων
DE602004030545D1 (de) Behandlung proliferativer erkrankungen mit epothilon-derivaten und bestrahlung